Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP0250 plus Bortezomib and Dexamethasone in RRMM
NCT03136653Phase 2Completed
- Sponsor
- Molecular Partners AG
- Start
- May 2017
- Primary completion
- Oct 2020
- Modality
- Carrier/Scaffold Proteins
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of MP-0250 in multiple myeloma (MM), sponsored by Molecular Partners AG. Primary endpoint: Overall Response Rate at 24 months. Started May 2017; status: completed.
02
Drugs
MP-0250
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03136653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136653.